Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer With Durable Disease Control: A Randomized Low-intervention Phase II Trial of the AIO Working Groups Breast Cancer and Quality of Life
This is a low-intervention, randomized, non-comparative, open-label, multicenter, prospective, phase II trial investigating discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control.
100 Clinical Results associated with Institut fr Klinische Krebsforschung IKF GmbH
0 Patents (Medical) associated with Institut fr Klinische Krebsforschung IKF GmbH
100 Deals associated with Institut fr Klinische Krebsforschung IKF GmbH
100 Translational Medicine associated with Institut fr Klinische Krebsforschung IKF GmbH